NCT03924466View on ClinicalTrials.gov

Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

November 30, 2024

Study Completion Date

December 31, 2024

Conditions
Metastatic Breast CarcinomaLocally Advanced Breast CancerCancer of PancreasSolid Tumor With Intermediate or High HER2 ExpressionSalivary Gland CancerGastric CancerEndometrial CancerUterine CancerNon Small Cell Lung CancerBiliary Tract CancerCholangiocarcinomaColorectal CancerUrothelial CarcinomaProstate Cancer
Interventions
DRUG

68GaNOTA-Anti-HER2 VHH1

"All subjects will receive at least one single intravenous injection of the IMP followed by a total body PET/CT prior to receiving standard-of-care therapy.~A second injection of the IMP can be administered before or during standard-of-care treatment, depending on cohort."

Trial Locations (1)

1090

RECRUITING

Uz Brussel, Brussels

All Listed Sponsors
collaborator

Kom Op Tegen Kanker

OTHER

collaborator

Agentschap voor Innovatie door Wetenschap en Technologie, Project Toegepast Biomedisch onderzoek met een primair Maatschappelijke finaliteit.

UNKNOWN

lead

Universitair Ziekenhuis Brussel

OTHER

NCT03924466 - Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients | Biotech Hunter | Biotech Hunter